Organization | Centro Cardiologico Monzino IRCCS

Centro Cardiologico Monzino IRCCS Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial

2019

NCT04154982

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Centro Cardiologico Monzino | Centro Cardiologico Monzino IRCCS | Centro Cardiologico Monzino, IRCCS

Active Ingredients

Drugs in Phase 4 Trials (5)

acetylsalicylic acid (aspirin) (1 trial)

clopidogrel (plavix) (1 trial)

diltiazem (cardizem) (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

warfarin (coumadin) (1 trial)

Drugs in Phase 2 Trials (2)

acetylcysteine (mucomyst) (1 trial)

evolocumab (repatha) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Arrhythmias, Cardiac (Phase 2)

Infarction (Phase 2)

Myocardial Infarction (Phase 2)

ST Elevation Myocardial Infarction (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 3
# of Trial APIs: 7